share_log

榮昌生物：海外監管公告 - 華泰聯合證券有限責任公司關於榮昌生物製藥（煙台）股份有限公司調整2024-2025 年度日常關聯交易預計的核查意見

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 26 08:59
Summary by Moomoo AI
荣昌生物（煙台）股份有限公司於2024年4月26日公告，其保荐机构华泰联合证券已对公司2024-2025年度日常关联交易预计金额进行了审慎核查。核查内容包括与关联方烟台迈百瑞国际生物医药股份有限公司及烟台赛普生物技术有限公司的交易情况。荣昌生物计划接受迈百瑞提供的劳务，并向赛普生物购买材料，交易价格遵循市场化原则。董事会、股东大会审议通过后，将与关联方签署具体合同。华泰联合证券认为本次关联交易合理、公平，且不会损害公司及股东利益，特别是中小股东利益。
荣昌生物（煙台）股份有限公司於2024年4月26日公告，其保荐机构华泰联合证券已对公司2024-2025年度日常关联交易预计金额进行了审慎核查。核查内容包括与关联方烟台迈百瑞国际生物医药股份有限公司及烟台赛普生物技术有限公司的交易情况。荣昌生物计划接受迈百瑞提供的劳务，并向赛普生物购买材料，交易价格遵循市场化原则。董事会、股东大会审议通过后，将与关联方签署具体合同。华泰联合证券认为本次关联交易合理、公平，且不会损害公司及股东利益，特别是中小股东利益。
RONG CHANG BIO (YANTAI) CO., LTD. ANNOUNCED ON APRIL 26, 2024 THAT ITS ADVISORY AGENCY HUATAI UNITED SECURITIES HAS CONDUCTED A PRUDENTIAL AUDIT OF THE COMPANY'S FORECAST AMOUNT FOR DAILY CONNECTED TRANSACTIONS FOR 2024-2025. THE AUDIT INCLUDES TRANSACTIONS WITH THE CONTACT YANTAI MAIBARI INTERNATIONAL BIOPHARMACEUTICAL CO., LTD. AND YANTAI CYP BIOTECHNOLOGY CO., LTD. RONG CHANG BIO PROGRAM ACCEPTS THE LABOR PROVIDED BY MAYBERRY AND PURCHASES MATERIALS FROM CYPRIOT BIOMICS, TRADING PRICES IN ACCORDANCE WITH THE PRINCIPLES OF MARKETING. After the Board of Directors and the General Meeting have been approved, a specific contract will be signed with the contact parties. Huatai United Securities considers that this transaction is reasonable, fair and will not prejudice the interests of the company and its shareholders, in particular the interests of small and medium-sized shareholders.
RONG CHANG BIO (YANTAI) CO., LTD. ANNOUNCED ON APRIL 26, 2024 THAT ITS ADVISORY AGENCY HUATAI UNITED SECURITIES HAS CONDUCTED A PRUDENTIAL AUDIT OF THE COMPANY'S FORECAST AMOUNT FOR DAILY CONNECTED TRANSACTIONS FOR 2024-2025. THE AUDIT INCLUDES TRANSACTIONS WITH THE CONTACT YANTAI MAIBARI INTERNATIONAL BIOPHARMACEUTICAL CO., LTD. AND YANTAI CYP BIOTECHNOLOGY CO., LTD. RONG CHANG BIO PROGRAM ACCEPTS THE LABOR PROVIDED BY MAYBERRY AND PURCHASES MATERIALS FROM CYPRIOT BIOMICS, TRADING PRICES IN ACCORDANCE WITH THE PRINCIPLES OF MARKETING. After the Board of Directors and the General Meeting have been approved, a specific contract will be signed with the contact parties. Huatai United Securities considers that this transaction is reasonable, fair and will not prejudice the interests of the company and its shareholders, in particular the interests of small and medium-sized shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more